Yin ShenCEO at Zhongmou TherapeuticsSpeaker
Profile
Dr. Yin Shen is the founder and CEO of Zhongmou Therapeutics, a clinical-stage biotechnology company developing gene and optogenetic therapies to restore vision in patients with retinal degenerative diseases. Under her leadership, the company has advanced ZM-02, a best-in-class optogenetic gene therapy currently in clinical trial (MOON study), offering a mutation-independent approach for conditions like retinitis pigmentosa.
In parallel with her industry role, Dr. Shen serves as a Distinguished Professor and Director of the Eye Institute at Wuhan University, and is an internationally recognized expert in neuro-ophthalmology and inherited retinal diseases. Dr. Shen's research focuses on the mechanisms of retinal degeneration, bipolar cell dysfunction, and therapeutic gene delivery strategies, with over 80 peer-reviewed publications in high-impact journals, including Cell Reports, Nature Communications, and Science Advances.
Dr. Shen's combined academic and entrepreneurial leadership positions her at the forefront of innovation in vision restoration.
Agenda Sessions
Next Generation: Zhongmou Therapeutics
, 09:50View Session